RMD

ResMed
D

RMD

Arincen97/100B

ResMed return on equity (ROE)

ResMed's return on equity is 45.95%: net income of 2.73B USD over the last twelve months on shareholders' equity of 5.95B USD.

Today
45.95%
Average, 5 years
24.19%
Low, 5 years
16.59%
High, 5 years
45.95%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 2.73B ÷ 5.95B = 45.95%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is ResMed's return on equity so high?

Net margin
26.9%
profit on each dollar of sales
Asset turnover
0.63×
sales on each dollar of assets
Equity multiplier
1.36×
assets on each dollar of equity
Return on equity
23.1%
FY2026
  • FY202626.9% × 0.63 × 1.36 = 23.1%
  • FY202527.2% × 0.63 × 1.37 = 23.5%
  • FY202421.8% × 0.68 × 1.41 = 21.0%
  • FY202321.3% × 0.63 × 1.63 = 21.7%
  • FY202221.8% × 0.70 × 1.52 = 23.2%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today45.95%2.73B5.95B
FY202630 Jun 202623.13%1.52B6.59B
FY202530 Jun 202523.47%1.40B5.97B
FY202430 Jun 202420.99%1.02B4.86B
FY202330 Jun 202321.73%897.56M4.13B
FY202230 Jun 202223.19%779.44M3.36B
FY202130 Jun 202116.44%474.51M2.89B
FY202030 Jun 202024.90%621.67M2.50B
FY201930 Jun 201919.52%404.59M2.07B
FY201830 Jun 201815.33%315.59M2.06B
FY201730 Jun 201717.46%342.28M1.96B
FY201630 Jun 201620.79%352.41M1.69B
FY201530 Jun 201522.23%352.89M1.59B
FY201430 Jun 201419.64%345.27M1.76B
FY201330 Jun 201319.07%307.13M1.61B
FY201230 Jun 201215.85%254.85M1.61B
FY201130 Jun 201113.11%226.99M1.73B
FY201030 Jun 201014.76%190.09M1.29B
FY200930 Jun 200913.13%146.45M1.12B
FY200830 Jun 200810.20%110.30M1.08B
FY200730 Jun 20077.12%66.30M931.22M
FY200630 Jun 200611.95%88.21M738.15M
FY200530 Jun 200513.67%64.79M474.07M
FY200430 Jun 200415.85%57.28M361.50M
FY200330 Jun 200315.96%45.73M286.43M
FY200230 Jun 200219.44%37.51M192.93M
FY200130 Jun 200111.59%11.63M100.37M
FY200030 Jun 200023.65%22.23M93.97M
FY199930 Jun 199922.49%16.10M71.60M
FY199830 Jun 199820.87%10.60M50.80M
FY199730 Jun 199716.82%7.50M44.60M
FY199630 Jun 199611.54%4.50M39.00M
FY199530 Jun 19959.69%2.80M28.90M
FY199430 Jun 199421.43%1.20M5.60M
FY199330 Jun 199327.59%800.00K2.90M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about ResMed's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.